Clinical trial
Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer
NCT00021424 · National Institute on Deafness and Other Communication Disorders (NIDCD), NIH · Completed
Key facts
| NCT number | NCT00021424 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer |
| Official title | Phase I/Pilot Study of Intralesional Immunotherapy With A Recombinant Avipox Virus Engineered To Express A Triad Of Co-Stimulatory Molecules In Patients With Advanced Squamous Cell Carcinoma Of The Head And Neck |
| Lead sponsor | National Institute on Deafness and Other Communication Disorders (NIDCD), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer, Metastatic Cancer |
| Intervention type | Biological |
| Interventions | recombinant fowlpox-TRICOM vaccine |
| Start date | Jun 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 30, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: